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Abstract
Introduction In everyday practice, angiotensin converting en-
zyme inhibitors and beta-blockers are cornerstone treatments
in patients with (cardio-)vascular disease. Clear data that eval-
uate the effects of the combination of these agents on morbid-
ity and mortality are lacking.
Methods In this retrospective pooled analysis of three large
perindopril outcome trials (ADVANCE, EUROPA,
PROGRESS), clinical outcomes were evaluated in 29,463 pa-
tients with vascular disease. Multivariate Cox regression anal-
yses were performed in patients randomized to a perindopril-
based regimen or placebo (treatment effect), and data were
stratified according to background beta-blocker treatment.
The primary endpoint was a composite of cardiovascular mor-
tality, non-fatal myocardial infarction, and stroke.
Results The cumulative incidence of the primary endpoint
over mean follow-up of 4.0 years (Sd 1.0) was significantly
lower in the beta-blocker/perindopril group (9.6%; 545/5700
patients) as compared to beta-blocker/placebo (11.8%; 676/
5718 patients) (p < 0.01). Adding perindopril to existing
beta-blocker treatment reduced the relative risk of the primary
endpoint by 20% (hazard ratio (HR) 0.80; 95% confidence
interval (CI) 0.71–0.90), non-fatal myocardial infarction by
23% (HR 0.77; 95% CI 0.65–0.91), and all-cause mortality
by 22% (HR 0.78; 95% CI 0.68–0.88) as compared to place-
bo. Significant treatment benefit was not observed for stroke
(HR 0.93; 95% CI 0.75–1.15). Significance was maintained
for the primary endpoint and cardiovascular endpoints when
data were further stratified by baseline hypertension.
However, the mortality benefit was only observed in patients
with hypertension with background beta-blocker use.
Conclusions These data suggest that the beneficial
cardioprotective effects of perindopril treatment are additive
to the background beta-blockers use.
Keywords ACE-inhibitor . Perindopril . Beta-blocker .
Hypertension . Prevention . Vascular disease
Introduction
In order to reduce morbidity and mortality, guidelines for hy-
pertension, coronary artery disease, and heart failure recom-
mend treatment with beta-blockers and angiotensin-
converting enzyme (ACE) inhibitors [1–3]. Beta-blockers
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are generally used to decrease blood pressure, manage ar-
rhythmias (i.e., prevent sudden cardiac death), and treat angi-
na pectoris and heart failure. Angiotensin-converting enzyme
inhibitors are used to reduce blood pressure, treat congestive
heart failure, and to provide cardioprotection in patients with
acute coronary syndromes [2].
Consistent with these recommendations, a wide range of
patients with cardiovascular diseases are treated daily with
beta-blockers and ACE-inhibitors [4]. Large cross-sectional
population studies have found, for instance, that beta-
blockers and ACE-inhibitors are prescribed in 86 and 65% of
patients with coronary disease and in 93 and 71% of patients
with heart failure, respectively [5, 6]. Data have also shown
that beta-blocker/ACE-inhibitor combinations are the most
frequently prescribed antihypertensive combination in real-
life clinical practice (15–22% of hypertensive patients) [4].
Perindopril is a widely prescribed ACE-inhibitor that is
supported by extensive pharmacokinetic, pharmacodynamic,
blood pressure, and outcome studies [7–12]. A previous meta-
analysis of the large EUROPA, ADVANCE, and PROGRESS
trials, which included a wide range of patients with vascular
disease, showed that perindopril-based regimens improved
survival and reduced the risk of having a major cardiovascular
event [13].
Few data that look specifically at the effect of a beta-
blocker/perindopril combination and its interaction on cardio-
vascular events have been published [14]. A subanalysis of the
EUROPA trial (N = 7534) has shown that beta-blocker/
perindopril treatment, when compared to beta-blocker/place-
bo, significantly reduced the relative risk of cardiovascular
death/non-fatal myocardial infarction (MI)/resuscitated cardi-
ac arrest (−24%; p = 0.002), MI (−28%; p = 0.001), and
hospitalization for heart failure (−45%; p = 0.025) [14]. As
the ADVANCE and PROGRESS trials also included a large
number of patients taking a beta-blocker as a background
treatment [10, 12], a retrospective pooled analysis of the
EUROPA, ADVANCE, and PROGRESS trials would offer
outcome data for a large cohort of patients with a wide range
of cardiovascular risk profiles. The objective of this analysis
was, therefore, to assess the benefit of perindopril treatment in
patients already taking beta-blockers and to study its additive
or synergistic effects in more detail. In particular, benefits of
beta-blocker/perindopril treatment were looked at in hyperten-
sive and non-hypertensive patients.
Methods
Methods were similar to those published by Brugts et al. [13].
Individual data from the ADVANCE, EUROPA, and
PROGRESS studies were pooled. As previously described,
the rationale for combining these trials is based on the fact
that all three trials studied the same agent, perindopril; we
provided the opportunity to include individual data in this
combined analysis, which made important subgroup analyses
possible at the patient level with individual data access. The
types of patients included in these studies were different in
their primary diagnoses, but since atherosclerosis and vascular
disease are not restricted to a single vascular bed, we conclude
that these patients are at least homogenous in having vascular
disease or being at a high risk of vascular disease. The com-
bined data set consisted of 29,463 patients, who were follow-
ed for an average of 4 years [13].
In all three trials, all patients were treated with a
perindopril-based regimen during the run-in period. Patients
were then randomized to a perindopril-based treatment or pla-
cebo for 4 years. In PROGRESS, patients had a history of
stroke or transient ischemic attack (TIA) and were randomized
to treatment with perindopril 4 mg ± indapamide 2.5 mg or
placebo [10]. In ADVANCE, patients had type 2 diabetes and
were randomized to combination treatment with perindopril
2–4 mg/indapamide 0.625–1.25 mg or placebo [12]. In
EUROPA, patients had stable coronary heart disease and were
randomized to treatment with perindopril 8 mg or placebo
[11]. In all three trials, background beta-blocker use was re-
corded. Dose and type of beta-blocker use was not available;
however, co-medication use was comprehensively noted.
Outcomes
In this analysis, the primary endpointwas a composite of car-
diovascularmortality,non-fatalMI,andstroke(identicalinall
threetrials).Secondaryendpointswereall-causemortality,car-
diovascularmortality,non-fatalMI,stroke,andtwocomposite
endpoints (cardiovascularmortality/non-fatalMIandcardio-
vascular mortality/non-fatal MI/revascularization).
Endpointswere assessed throughout the studyperiod. Study-
specificdefinitionswereusedaspreviouslydescribed[13].
Statistics
The randomization effect was preserved in all analyses by
studying the treatment effect of perindopril only. Data were
stratified according to beta-blocker therapy. Multivariate Cox
regression analyses were performed to calculate hazard ratios
(HR) and 95% confidence intervals (CIs). Adjustments (full
model) were made for baseline age, sex, hypertension, diabe-
tes mellitus, smoking, history of MI, history of percutaneous
coronary intervention/coronary artery bypass grafting, history
of stroke/TIA, and co-medication use (antiplatelet agents,
lipid-lowering agents, calcium antagonists, diuretics),
indapamide use, and active treatment (perindopril) dosage
(by trial). Additional adjustments for baseline risk, tests for
heterogeneity in treatment effects, and tests for heterogeneity
among trials were performed as previously described [13].
Hazard ratios and 95% CIs are presented with corresponding
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two-sided p values. Survival analyses were performed for all
treatment groups, and differences were evaluated using log
rank (Mantel-Cox) tests. In all analyses, a p value ≤ 0.05
was considered significant.
Data were further stratified according to the presence or
absence of hypertension at baseline. Hypertension was de-
fined as a systolic blood pressure (SBP)/diastolic blood pres-
sure (DBP) ≥ 160/95 mmHg or use of antihypertensive med-
ication according to the definition used in EUROPA [11] and
previous analyses [13]. As the definition of hypertension has
changed since the EUROPA trial was performed, the primary
endpoint was also assessed in additional post hoc subgroup
analysis using a cut-off for hypertension of SBP/DBP ≥ 140/
90 mmHg or the use of antihypertensive medication.
Results
The pooling of data from ADVANCE, EUROPA, and
PROGRESS resulted in a study cohort of 29,463 patients at
high cardiovascular risk.
During the 4-week run-in period, during which all patients
received perindopril, SBP/DBP decreased by a mean of
−7.8 ± 16.0/−3.6 ± 9.0 mmHg in patients taking beta-blockers
(n = 11,418) and by a mean of −8.6 ± 16.0/−4.0 ± 9.0 mmHg in
patients not taking beta-blockers (n = 18,045). Differences be-
tween groups were not significant in BP reduction.
Among the 11,418 patients (38.8%) taking a background
beta-blocker, 5700 patients (49.9%) to the perindopril-
based regimen (beta-blocker/perindopril group) and 5718
patients (50.1%) had been randomized to placebo (beta-
blocker/placebo group). Among the 18,045 patients
(61.2%) not taking a background beta-blocker, 9030 pa-
tients (50.0%) to perindopril (no beta-blocker/perindopril
group) and 9015 patients (50.0%) had been randomized to
placebo (no beta-blocker/placebo group). Patient character-
istics for the total study population and strata are presented
in Tables 1 and 2.
The primary endpoint (cardiovascular mortality/non-fatal MI/
stroke) occurred in 1221 of the 11,418 patients in the beta-
blocker stratum (10.7%; HR 0.80; 95% CI 0.71–0.90): 676 pa-
tients in the beta-blocker/placebo group (11.8%) and 545 patients
Table 1 Baseline characteristics
in combined study population
(n = 29,463)
ADVANCE
(n = 11,140)
EUROPA
(n = 12,218)
PROGRESS
(n = 6105)
TOTAL
(n = 29,463)
Characteristics
Age (years), mean (SD) 66 (6) 60 (9) 64 (10) 63 (9)
Female, % 42.5 14.6 30.3 28.4
Previous MI, % 12.0 64.8 7.0 32.8
Previous PCI/CABG, % 8.5 54.9 2.7 26.6
Previous CVA/TIA, % 12.9 3.4 99.9a 27.0
Current smokers, % 15.1 15.2 20.0 16.2
Diabetes, % 100.0 12.3 12.5 45.5
Hypertension, % 68.7 27.1 47.8 54.1
Hypercholesterolemia, % 58.9 63.3 – 61.2b
Systolic blood pressure (mm Hg) 145 (21) 137 (15) 147 (9) 142 (19)
Diastolic blood pressure (mmHg) 81 (11) 82 (8) 86 (11) 82 (10)
Medications
Antiplatelet agents, % 46.7 92.3 72.3 70.8
Beta-blockers, % 24.5 61.7 17.0 38.8
Lipid-lowering agents, % 35.3 55.9 14.1 39.5
Calcium antagonists, % 30.8 31.4 39.9 33.3
Diuretics use, %c 9.2 23.7 11.5 15.1
Summary statistics for continuous variables are presented as mean (SD). Categorical data are summarized as
percentages. The definition of hypertension was unified in all trials, with EUROPA as template, as a blood
pressure of ≥ 160/95 mmHg or use of antihypertensives
CABG coronary artery bypass grafting, CVA cerebrovascular disease, MI myocardial infarction, PAD peripheral
arterial disease, PCI percutaneous coronary intervention, SD standard deviation, TIA transient ischemic attack
a PROGRESS, percentage was 61.2% (14294) based on 23,358 patients (ADVANCE and EUROPA)
bHypercholesterolaemia data were not present in PROGRESS
cDiuretics use other than indapamide study medication
Reproduced with permission from Brugts et al. (2009)
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in the beta-blocker/perindopril group (9.6%). The primary end-
point also occurred in 2057 of the 18,045 patients in the no beta-
blocker stratum (11.4%; HR 0.83; 95% CI 0.76–0.91): 1112
patients in the no beta-blocker/placebo group (12.3%) and 945
patients in the no beta-blocker/perindopril group (10.5%). The
cumulative incidence of patients who reached the primary end-
point over the follow-up period was lowest in the beta-blocker/
perindopril group (Fig. 1).
Subanalyses in Beta-Blocker Strata
Secondary endpoints for the beta-blocker stratum (n = 11,418)
are presented in Fig. 2. Perindopril treatment was associated with
decreased risk of cardiovascular mortality/non-fatal MI/
revascularization (HR 0.81; 95% CI 0.74–0.90), cardiovascular
mortality/non-fatal MI (HR 0.75; 95% CI 0.66–0.85), non-fatal
MI (HR 0.77; 95% CI 0.65–0.91), all-cause mortality (HR 0.78;
95%CI 0.68–0.88), and cardiovascular mortality (HR 0.73; 95%
CI 0.61–0.85) compared with placebo (Fig. 2). Treatment effect
was not significant for stroke (HR 0.93; 95%CI 0.75–1.15). The
p value for treatment interaction of beta-blocker use was signif-
icant for all-cause mortality and cardiovascular mortality (full
data shown in Tables 3 and 4). Cumulative incidence of all-
cause mortality throughout the follow-up period was significant-
ly lower (p < 0.01) in the beta-blocker/perindopril group than in
the beta-blocker/placebo group (Fig. 3).
Patients were further stratified according to baseline hyper-
tension. Results for the beta-blocker stratum (n = 11,418) are
presented in Fig. 4. In the subgroup of hypertensive patients
(n = 5838) using beta-blockers, perindopril treatment was as-
sociated with significant risk reduction compared to placebo
for the endpoints of cardiovascular mortality/non-fatal MI/
stroke (HR 0.77; 95% CI 0.66–0.89; p = 0.001), non-fatal
MI (HR 0.74; 95% CI 0.58–0.94; p = 0.02), and all-cause
mortality (HR 0.68; 95% CI 0.57–0.82; p = 0.001). Risk re-
duction was not significant for stroke (HR 0.90; 95% CI 0.70–
1.16; p = 0.4). In the subgroup of non-hypertensive patients
(n = 5580), perindopril significantly reduced cardiovascular
mortality/non-fatal MI/stroke (HR 0.84; 95% CI 0.71–1.00;
p = 0.04), and treatment benefit was consistent also without
Table 2 Baseline characteristics
of treatment groups and beta-
blocker strata in the combined
study population (n = 29,463)
Placebo Perindopril-based regimen
No beta-blocker
(n = 9015)
Beta-blocker
(n = 5718)
No beta-blocker
(n = 9030)
Beta-blocker
(n = 5700)
Characteristics
Age (years), mean (SD) 64 (8) 62 (9) 64 (8) 61 (9)
Female, % 31.8 23.2 31.8 22.7
Previous MI, % 20.5 51.9 20.8 52.2
Previous PCI/CABG, % 18.6 39.7 18.1 39.4
Previous CVA/TIA, % 34.8 14.5 35.2 14.1
Current smokers, % 17.2 15.1 17.3 13.8
Diabetes, % 52.9 34.1 53.6 32.4
Hypertension, % 55.7 51.8 56.2 50.5
Hypercholesterolemia, %a 57.1 66.3 57.3 66.0
Systolic BP, mean (SD) 143 (19) 141 (19) 143 (19) 140 (19)
Diastolic BP, mean (SD) 82 (10) 82 (9) 82 (10) 82 (9)
Medications
Antiplatelet agents, % 62.3 84.4 62.3 84.1
Beta-blocker agents, % 100 0 100 0
Lipid-lowering agents, % 31.7 52.5 31.2 51.8
Calcium antagonists, % 35.2 30.6 35.2 30.1
Diuretics, %b 13.6 16.1 14.0 15.2
Descriptive statistics are presented as mean (SD) for continuous variables and as percentages for categorical
variables. Hypertension was defined according to the EUROPA definition (blood pressure ≥ 160/95 mmHg or
use of antihypertensives)
CABG coronary artery bypass grafting,BP blood pressure inmmHg,CVA cerebrovascular disease,MImyocardial
infarction, PAD peripheral arterial disease, PCI percutaneous coronary intervention, SD standard deviation, TIA
transient ischemic attack
a Hypercholesterolemia data were not reported in PROGRESS. Percentages were based on a total of 23,358
patients (ADVANCE + EUROPA)
bDiuretics use excluding indapamide study medication
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beta-blocker use. Most surprisingly, the beneficial effect on
all-cause mortality was lost in non-hypertensive patients.
Significant interaction between the beneficial effect of beta-
blocker and perindopril was found for all-cause mortality in
hypertensive patients and not in non-hypertensive patients (p
for interaction beta-blocker/perindopril 0.9 for no hyperten-
sion and 0.01 for hypertension).
When the analysis was performed using the current newer
definition of hypertension (SBP/DBP ≥ 140/90), the treatment
effect of the perindopril-based regimen on the primary end-
point was similar (beta-blocker stratum) with identical infer-
ences (data not shown).
Discussion
In this retrospective pooled analysis of three large perindopril
outcome trials in patients at high cardiovascular risk, we found
that adding a perindopril-based regimen to existing beta-
blocker treatment reduced the risk of the primary composite
endpoint of cardiovascular mortality, non-fatal MI, and stroke
by 20% and secondary endpoints such as non-fatal MI by
23%, all-cause mortality by 22%, and cardiovascular mortal-
ity by 27% compared to placebo. These data suggest that the
beneficial effects of perindopril treatment on patients’ survival
are additive to the well-documented cardioprotective effects
of beta-blockers [15–20]. Treatment with beta-blockers, for
instance, has been shown to reduce mortality rates in patients
with acute coronary syndrome [15, 21].
Perindopril outcome results are consistent with previously
published data that have shown that perindopril treatment is
associated with decreased rates of cardiovascular events and
mortality in a broad range of patients with vascular disease
[10–12, 22]. In particular, in the Van Vark et al. meta-analysis
of 20 cardiovascular morbidity-mortality trials, perindopril
data from the ASCOT-BPLA, ADVANCE, and HYVET trials
drove the mortality benefits observed with ACE-inhibitors
[22]. Direct and indirect comparisons between ACE-
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Fig. 1 Cumulative incidence survival function of the primary endpoint in
29,463 patients by Cox regression analysis. The primary endpoint was
defined as the composite of cardiovascular mortality, non-fatal
myocardial infarction, and stroke. Subgroups were defined as no beta-
blocker/placebo (n = 9015; solid red line), beta-blocker/placebo
(n = 5718; solid black line), no beta-blocker/perindopril (n = 9030;
dotted red line), and beta-blocker/perindopril (n = 5700; dotted black
line). Cumulative incidence in percentages (%) and follow-up duration
in years are represented on the y-axis and x-axis, respectively
Fig. 2 Treatment effect of perindopril-based regimen in beta-blocker
stratum: Forest plot. A Cox regression multivariate analysis was
performed to calculate HRs and 95% CIs with adjustments for full
model. The primary endpoint was the composite endpoint of
cardiovascular mortality, non-fatal MI, and stroke. Among the 11,418
patients taking a beta-blocker, 5700 were randomized to a perindopril-
based regimen and 5718 to placebo. P interaction was significant for all-
cause mortality and CV mortality; all other p interactions are ns. CI,
confidence interval, CV cardiovascular, HR hazard ratio, MI myocardial
infarction, revasc revascularization, TIA transient ischemic attack
Cardiovasc Drugs Ther (2017) 31:391–400 395
inhibitors have also confirmed the cardioprotective benefits of
perindopril treatment [23, 24].
The cardioprotective and blood pressure reduction effects
that we observed are likely due to complementary mecha-
nisms of action. Treatment with a beta-blocker would be ex-
pected to prevent the release of renin that occurs as a feedback
mechanism when perindopril inhibits the renin angiotensin
aldosterone system [25]. Lowering renin levels could further
reinforce the benefits of perindopril treatment by diminishing
the risk of treatment failure. In addition, perindopril, when
compared to other ACE-inhibitors, is a particularly potent
inhibitor of bradykinin metabolism. Preserving bradykinin
levels promotes vascular health by reducing blood pres-
sure, oxidative stress, endothelial apoptosis, thrombin-
induced platelet activation, inflammation, and fibrosis
[25–32]. The effect of bradykinin preservation on vascular
health, beyond blood pressure control, has yet to be un-
derstood in the context of beta-blockade. However, the
data presented herein suggest that treating a patient with
perindopril on a beta-blocker background supports the
ability of perindopril to promote cardioprotection and vas-
cular health given the additive risk reduction.
Table 3 Overview of outcome
data (treatment effect perindopril
vs placebo) in strata of beta-
blocker and no-beta-blocker use
for all endpoints
Endpoint No beta-blocker (n = 18,045) Beta-blocker use (n = 11,418) Interaction
Events HR 95% CI Events HR 95% CI p int
Primary endpoint 2057 (11.4) 0.83 0.76–0.91 1221 (10.7) 0.80 0.71–0.90 0.63
CV mortality,
non-fatal MI
1289 (7.1) 0.88 0.79–0.98 990 (8.7) 0.75 0.66–0.85 0.09
Non-fatal MI 540 (3.0) 0.84 0.71–0.99 560 (4.9) 0.77 0.65–0.91 0.48
Stroke 1030 (5.7) 0.79 0.70–0.90 330 (2.9) 0.93 0.75–1.15 0.19
All-cause mortality 1486 (8.2) 0.96 0.88–1.06 813 (7.1) 0.78 0.68–0.88 0.02
CV mortality 819 (4.5) 0.93 0.83–1.07 492 (4.3) 0.73 0.61–0.85 0.04
A Cox regression multivariate analysis was performed to calculate HRs and 95% CIs with adjustments for full
model. The primary endpoint was the composite endpoint of cardiovascular mortality, non-fatal MI, and stroke.
Among the 18,045 patients without background beta-blocker use, 9030 were randomized to a perindopril-based
regimen and 9015 to placebo. Among the 11,418 patients taking a beta-blocker, 5700 were randomized to a
perindopril-based regimen and 5718 to placebo
CI confidence interval, CV cardiovascular, HR hazard ratio,MI myocardial infarction
Table 4 Full data in beta-blocker and no beta-blocker strata for baseline hypertension analysis
No beta-blocker use (n = 18,045) Beta-blocker use (n = 11,418) Interaction
Events % HR 95% CI Events % HR 95% CI p value
Primary endpoint No hypertension 741 9.3 0.85 0.74–0.98 518 9.3 0.84 0.71–1.00 0.86
Hypertension 1316 13.0 0.82 0.74–0.92 703 12.0 0.77 0.66–0.89 0.33
CV mortality, non-fatal MI No hypertension 501 6.3 0.81 0.68–0.97 788 7.8 0.92 0.79–1.11 0.05
Hypertension 460 8.2 0.82 0.68–0.98 530 9.1 0.68 0.58–0.82 0.48
Non-fatal MI No hypertension 258 3.2 0.81 0.63–1.03 292 5.2 0.79 0.62–0.99 0.70
Hypertension 282 2.8 0.88 0.70–1.11 268 4.6 0.74 0.58–0.94 0.46
Stroke No hypertension 310 3.9 0.91 0.72–1.13 86 1.5 0.99 0.65–1.52 0.56
Hypertension 720 7.1 0.75 0.65–0.87 244 4.2 0.90 0.70–1.16 0.26
All-cause mortality No hypertension 546 6.9 0.94 0.79–1.10 326 5.8 0.93 0.74–1.15 0.90
Hypertension 940 9.3 0.98 0.87–1.12 487 8.3 0.68 0.57–0.82 0.01
CV mortality No hypertension 264 3.3 0.84 0.66–1.07 191 3.4 0.87 0.66–1.16 0.72
Hypertension 555 5.5 0.97 0.83–1.17 301 5.2 0.65 0.51–0.82 0.01
Among patients with no background beta-blocker use (n = 18,045), 7944 had no history of hypertension and 10,101 had hypertension at baseline.
Among patients with beta-blocker use (n = 11,418), 5580 had no history of hypertension at baseline and 5838 had hypertension at baseline. A Cox
regression multivariate analysis was performed to calculate HRs and 95% CIs with adjustments for full model. The primary endpoint was the composite
endpoint of cardiovascular mortality, non-fatal MI, and stroke. Results for other endpoints are similar
CI confidence interval, CV cardiovascular, HR hazard ratio, MI myocardial infarction
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Regardless of what is known about mechanism of action,
studies have shown that physicians often believe that the an-
tihypertensive efficacy of ACE-inhibitors prescribed on top of
a beta-blocker is not fully additive. Here, with this analysis,
we were able to study whether such an effect exists. We show
that at the end of the run-in period, treatment with perindopril
decreased blood pressure regardless of background beta-
blocker prescription and to the same degree in both groups
(beta-blocker vs no beta-blocker). In other studies, such as the
CONFIDENCE trial, adding perindopril to existing beta-
blocker treatment led to significant decreases in blood pres-
sure after 3 months [33].
Our data also illustrate the complexity of the molecular
pathways at play. The beneficial effect of beta-blocker/
perindopril treatment compared with beta-blocker/placebo
treatment was significant for the primary endpoint and non-
fatal MI in both hypertensive and non-hypertensive patients.
In real-life settings, the extent of blood pressure reduction
and cardioprotective efficacy would most likely be marred by
poor compliance. A 2008 Kaiser Permanente database analy-
sis, for example, has shown that roughly 29% of patients with
coronary artery disease were not compliant with their beta-
blocker prescription and that non-compliance was associated
with significantly higher risk of cardiovascular mortality (HR
1.53, 95% CI 1.16–2.01), all-cause mortality (HR 1.50, 95%
CI 1.33–1.71), and revascularization procedures (HR 1.15,
95% CI 1.04–1.27) [34]. Other publications have estimated
that 9% of cardiovascular disease events in Europe can be
attributed to poor adherence to vascular medication and that
good adherence to therapy decreases mortality risk [35, 36].
These data underscore the need to develop strategies in which
patients can benefit from the full effect of treatment.
Among possible strategies, besides patient education by
physicians and pharmacists, single-pill combinations are rec-
ommended by European guidelines to increase adherence
[37]. They are associatedwith higher rates of adherence, better
blood pressure control, and lower rates of cardiovascular
events than free associations of components [38, 39]. Thus,
a single-pill combination that would include perindopril and a
beta-blocker would respond to a real need for single-pill com-
binations as a potential new option to reach further treatment
benefits.
Beta-blocker type was not available in this analysis. The
beta-blockers metoprolol and bisoprolol are the types most
frequently prescribed in the world. Bisoprolol is a long-
acting beta-blocker that is predominantly selective for β1-
adrenoreceptors and that can be combined with perindopril
in a single-pill formulation because, like perindopril, it has a
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Fig. 3 Cumulative incidence of all-cause mortality in patients
randomized to perindopril-based regimen and placebo in the beta-
blocker stratum. Subgroups were defined as beta-blocker/placebo
(n = 5718; solid black line) and beta-blocker/perindopril (n = 5700;
dotted black line). Cumulative incidence in percentages (%) and follow-
up duration in years are represented on the y-axis and x-axis, respectively
Fig. 4 Treatment effect of ACE-inhibitor-based regimenwith perindopril
in the stratum of beta-blocker use according to baseline hypertension:
Forest plot. Subanalyses were performed according to baseline
hypertension. Of the 5700 patients in the beta-blocker/perindopril
group, 2876 patients had HTN (50.5%). Of the 5718 patients in the
beta-blocker/placebo, 2962 patients had HTN (51.8%). A Cox
regression multivariate analysis was performed to calculate HRs and
95% CIs with adjustments for full model. CI confidence interval, CV
cardiovascular, HR hazard ratio, HTN hypertension, MI myocardial
infarction, ns not significant. P for interaction all-cause mortality 0.01;
all other p interaction terms ns
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24-h duration of action [7, 40, 41]. Bisoprolol also benefits
from a well-documented safety profile and has been classified
as an essential drug for hypertension, angina, heart failure, and
arrhythmia by the World Health Organization [42]. Its combi-
nation with perindopril is supported by data which have
shown that bisoprolol/perindopril is safe and effective in
blood pressure studies [32]. As the current analysis demon-
strates a strong consistent treatment benefit of the ACE-
inhibitor perindopril in patients with vascular disease on top
of beta-blocker use and as this additive effect seems even
more pronounced in patients with hypertension, the combina-
tion of perindopril and bisoprolol in a single-pill combination
may offer treatment solutions to improve adherence.
Of note is the absence of a treatment benefit for the end-
points of stroke independent of the presence of hypertension
or not, which is consistent with previous results. We did ob-
serve a mortality benefit of the combination perindopril on top
of beta-blocker use overall and in hypertensive patients with a
significant interaction effect between treatments used. In pa-
tients without hypertension, there was no effect on all-cause
mortality.
Limitations
Robustness of results in retrospective pooled analyses is often
undermined by heterogeneity among trials. In order to reduce
heterogeneity, we only included outcome trials with similar
designs. All three studies, EUROPA, PROGRESS, and
ADVANCE, were 4-year prospective, randomized, placebo-
controlled trials that included patients with cardiovascular dis-
ease or patients at high risk of developing cardiovascular dis-
ease. Trial-specific definitions were used even though defini-
tions and thresholds were not identical because statistical re-
sults have been shown to tolerate some heterogeneity in end-
point definitions [43]. In addition, we limited our trial selec-
tion to trials in which patients were randomized to a
perindopril-based regimen. The ASCOT-BPLA trial, for in-
stance, was not included because patients were randomized
to an amlodipine-based regimen to which perindopril was
added as needed [44]. The current analysis, thus, provides a
unique and robust data set that assesses the treatment effect of
perindopril in relation to background beta-blocker use.
Regarding beta-blocker use, we only have data on baseline
use. Doses of beta-blockers were not recorded. We, therefore,
cannot evaluate how dose might have influenced outcome
results. During the trials, standard of care was changing with
the use of the combination of calcium antagonist and beta-
blockers; such a time-trend may have confounded the effects.
Additionally, during the course of the perindopril trials, there
was the introduction of the long-acting metoprolol succinate
in the presence of ongoing metoprolol tartrate usage No data
on side-effects of beta-blockers or treatment effect heteroge-
neity were available related to beta-blocker use, which was
described for perindopril use in these trials in detail previously
[10–12, 45–47]. Finally, statistical power is lower in subgroup
analyses.
Conclusions
In this meta-analysis, a consistent treatment benefit was ob-
served with a perindopril-based regimen on a background of
beta-blocker use. This treatment benefit was most pronounced
relatively in patients with hypertension, which could suggest
an additive effect of both treatments.
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